MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts

MabVax Main Banner_Green Background.jpg.opt1258x492o0,0s1258x492

MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts

Story continues below

NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).


Ford explains that Mabvax is attractive due to multiple potential upcoming catalysts. According to the report, “This is an exciting time for MabVax (OTCQB:MBVX), shareholders because the company’s share price could rise from $2 to over $5 in the next few weeks based on MabVax’s extreme level of undervaluation and 2 imminent catalysts.”


Today Mabvax is trading on strong volume based on the continued investment by Dr. Phillip Frost and Opko (NYSE OPK), which has the shares trading slightly higher.


The report can be found at



Some of the highlights from Ford’s research:


  • MabVax is completely undiscovered by Wall Street and would be undervalued even if the share price doubled.
  • Phillip Frost and Opko (NYSE OPK) just invested in MabVax and given Dr. Frost’s track record, MabVax could be another home run trade.
  • In neuroblastoma trials MabVax demonstrated its drug is almost twice as effective as the standard of care.
  • The Cancer Immunotherapy Index has risen almost 50% this year and MabVax is a major contender in that sector



About Market Exclusive

Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.




The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.




SOURCE: Market Exclusive

An ad to help with our costs